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3D cell culture including different cell types, such as immune cells, is a representative
platform that mimics the tumor microenvironment. Here we disclose an easy-to-handle
3D co-culture protocol using a scaffold-free technique with the breast cancer cell
line MDA-MB-231 and breast cancer patient-derived immune cells from peripheral
blood. The method presented is simple, less time-consuming and less expensive when
compared to other 3D techniques. Additionally, this is an optimized protocol for the
establishment of a 3D system for this cell line, which is normally seen as challenging
to spontaneously form spheroids. The addition of patient-derived immune cells to the
cancer cells’ spheroid allows the study of the crosstalk between both cell types, as
well as the assessment of individual therapeutic approaches to intensify the antitumor
immune response. In fact, with this model, we observed that patients’ immune cells
exhibit a wide range of antitumor responses and we further demonstrated that it is
possible to manipulate the less effective ones with a canonical stimulus, as a proof-
of-concept, in order to improve their ability to lower the viability of tumor cells. Therefore,
this platform could be applied for a personalized immune-based drug screening, with
results after a maximum of 10 days of culture, in order to develop more tailored breast
cancer treatments and ameliorate patients’ survival rate.
Keywords: 3D culture, spheroids, breast cancer, tumor immune microenvironment, drug screening,
immunotherapy
INTRODUCTION
Breast cancer remains the main leading cause of cancer-related deaths in women worldwide (1). A
growing body of evidence supports that breast cancer prognosis may be related to the individual
immune system functional status (2), whichmay explain, at least in part, why some patients respond
to the established treatments, whilst others do not (3). Indeed, tumors have mechanisms to escape
the immune system surveillance, which includes the release of anti-inflammatory cytokines (such as
TGF-β or IL-10), the activation of immune checkpoints and the recruitment of suppressive immune
cell types (4).
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To overcome this immune escape, immunotherapies can be
implemented. In fact, increasing numbers of immunotherapies
for cancer treatment have been coming to the market over
the past decade, revolutionizing the way many cancers are
treated, especially lung cancer and melanoma, which drastically
improved patients’ outcome (5, 6). Nevertheless, patient response
rates can fluctuate among cancers and within cohorts with the
same malignancy, for reasons that are not so well understood,
but that should include different immune competency, antigen
specificity and expression levels (7, 8). For other common
cancers, including breast cancer, immunotherapy, in particular
with the most known FDA approved immune checkpoint
blockers, such as PD-1 (programmed cell death protein 1),
PD-L1 (programmed death-ligand 1), and CTLA-4 (cytotoxic
T-lymphocyte-associated protein 4), have been shown a low
success rate (9, 10), with only Atezolizumab (anti-PD-L1) being
approved for the treatment of metastatic triple negative breast
cancer (TNBC).
Bearing in mind that specific reactivation of patients’ immune
system is one of the major goals to improve breast cancer
treatment, though the mechanisms refraining the antitumor
immune responses might be different from patient to patient,
it is important to further develop immunotherapies that work
in individual patients. The tumor immune microenvironment
(TIME) has been widely studied in breast cancer, in order to
find new personalized therapeutic strategies based on immune-
modulators that could aid the standard chemotherapeutic
options and improve breast cancer patients’ survival (11).
In order to screen novel therapies, the development of new
platforms that reliably mimic tumor structures should be
addressed. Mice models hardly mimic the treatment resistance
and the immune response observed in patients, and human
models consisting of monolayer cultures (2D) poorly recapitulate
the complexity of the tumor environment. Thus, many studies
have been emphasizing the use of human 3D cultures to
study with more accuracy the efficacy of different anticancer
treatments. Additionally, their formation and assessment are
less time-consuming when compared to animal models (12).
3D in vitro cell culture offer more efficient cell-cell and cell-
matrix interactions, which influences cell structure, cell signaling,
cell adhesion and mechano-sensing. Moreover, the diffusion of
oxygen and nutrients is hampered to the hypoxic core of the
structure and produced metabolites are also poorly diffused from
the core to the surface of the 3D structure (13, 14). Finally, 3D
systems allow for the addition of different cell types, creating a
multicellular structure, necessary for the study of the TIME and
alternative therapeutic options (15, 16).
Nevertheless, there are multiple ways to develop a 3D culture
system. Here, we disclose a protocol for a liquid overlay
technique, which consists in coating the plate with a non-
adhesive component to enhance cell-cell interaction, allowing
a spontaneous 3D spheroid formation (17). This approach is
scaffold-independent, easy to work and handle, reproducible
and less expensive, when compared to the use of commercial
low adherence plates or even scaffold-based approaches that use
Matrigel or collagen, for instance (17, 18). Another advantage is
the low number of cells needed to form the 3D structure, which
is a beneficial characteristic when working with patient-derived
cells. Although other protocols have been established for the
formation of breast cancer spheroids with immune cell invasion,
here we reveal a protocol specifically for MDA-MB-231 cell line,
which is often seen as a difficult cell line to spontaneous form
spheroids without scaffolds (19, 20). The employment of this cell
line in drug-screening platforms is particularly relevant because
it is a highly aggressive, invasive and poorly differentiated TNBC
cell line. TNBC lacks the estrogen and progesterone receptor (ER
and PR) expression, as well as the human epidermal growth factor
receptor 2 (HER2), currently having limited treatment options
(21). Interestingly, this cell line, differently from other common
breast cancer cell lines, such as MCF-7, express high levels
of the immune checkpoint PD-L1 (22), which can bind to its
receptor PD-1 at the surface of effector T lymphocytes, therefore
acting as a brake and impairing the activation and the assemble
of a proper antitumor response. PD-L1, a key component
of the tumor immune evasion mechanisms, is indeed highly
expressed in many breast cancer patients’ tumors, especially
in cases with poorly activated tumor-infiltrating effector T
lymphocytes (3).
Additionally, with this protocol, it is possible to perform a co-
culture in a 1:1 ratio of tumor cells to immune cells and observe
the effect of the later in the tumor. This is an advantage when
comparing to other protocols with a 10:1 ratio of immune cells
to tumor cells (23), since it is more representative of in vivo
immune cells infiltration into the tumor microenvironment, as
we observed previously (3).
Thus, besides describing in detail the protocol employed for
the establishment of this 3D system, we also demonstrate the
utility of this allogeneic system−3D co-culture of MDA-MB-
231 cell line with breast cancer patient-derived immune cells—
in the development of novel therapies, as treating the immune
cells with an external canonical stimulus could improve their
cytotoxic activity against the tumor cells. We believe that this
system can become extremely useful to test, in a simple and
economic fashion, several clinical grade immune-modulators
that alone or in combination with chemotherapeutic compounds
could improve the anti-tumor response of individual breast
cancer patients.
Likewise, this protocol also has the advantage of possible
modifications to include different cell types such as fibroblasts




1. MDA-MB-231 (ATCC R©HTB-26TM)
2. Dulbecco’s Modified EagleMedium (DMEM, Biowest, catalog
number: L0102-500), store at 4◦C
3. Fetal Bovine Serum (FBS, Sigma Aldrich, catalog number:
F9665-0500), store at−20◦C
4. Penicillin/Streptomycin (Pen/Strep, GE Healthcare, catalog
number: SV30010), store at−20◦C
5. TrypLE (Gibco, catalog number: 12605028), store at 4◦C
6. RPMI-1640 (Gibco, catalog number: 21875-034), store at 4◦C
7. Trypan blue (GE Healthcare, catalog number: SV30084.01),
store at room temperature
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8. 6-well plates for tissue culture (VWR, catalog number: 734-
2323)
9. Ficol (Biocol, Merck Millipore, catalog number: L6715), store
at room temperature
10. PBS 1X (see recipes), store at room temperature
11. Dimethyl sulfoxide (DMSO, Sigma, catalog number: D5879),
store at room temperature
12. Blood collection tubes with EDTA (BD Biosciences,
Vacutainer EDTAK2, catalog number: BD367525)
13. Pasteur pipettes (Sarstedt, catalog number: 86.1171.001)
14. Agarose (Invitrogen, catalog number: 16500–500), store at
room temperature
15. Distilled water (dH2O)
16. 96-well plates with round bottom (Sigma Aldrich, catalog
number: M9436-100EA)
17. 15mL falcons (VWR, catalog number: 525-0604)
18. 50mL falcons (VWR, catalog number: 525-0610)
19. 1.5mL microtubes (Enzifarma, catalog number: P10202)
20. Optional: Cell Trace CFSE proliferation kit (Invitrogen,
catalog number: C34554), store at−20◦C
21. Optional: CellTrackerTM Orange CMTMR (5- (and-6)–
(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine)
(Invitrogen, catalog number: C2927), store at−20◦C
22. Optional: Phorbol 12-myristate 13-acetate (PMA, Sigma
Aldrich, catalog number: P1585), store at−20◦C
23. Optional: ionomycin (Merck, catalog number: 407952), store
at−20◦C
24. Optional: BD HorizonTM Fixable Viability Stain 450 (BD
Biosciences, catalog number: 562247), store at−20◦C
25. Optional: FlowFix (Polysciences, catalog number: 25085-1),
store at 4◦C
26. Optional: mouse anti-human CD45-PercP (Biolegend,
catalog number: 304026), store at 4◦C
27. Optional: Human IFN-gamma ELISA MAXTM Standard






5. Biosafety cabinet with vertical flow (ESCO, LA2-4A1)
6. 37◦C CO2 incubator
7. Water bath able to reach 90◦C
8. Hemocytometer
9. Autoclave
10. Fluorescence microscope (Zeiss, model Axiovert 40 CFL) or
confocal microscope (Zeiss, model LSM710)
11. Flow cytometer (BD, FACS Canto II).
Software
1. GraphPad Prism v.7
2. FlowJo v.10
3. Image J 1.52c.
Recipes
1. PBS 1X





b. Dissolve in 1800mL MilliQ H2O and mix well.
c. Adjust the pH to 7.4.
d. Add MilliQ H2O until a total volume of 2 L.
e. Prepare PBS 1X by adding:
100ml PBS 10X
900ml MilliQ H2O
f. Mix well and send it to autoclave.
2. Supplemented DMEM
a. Add 10% of FBS and 1% of Pen/Strep to total DMEM.
3. Supplemented RPMI
a. Add 10% of FBS and 1% of Pen/Strep to total RPMI.
Methods
Establishment of 3D Co-cultures
2D culture of MDA-MB-231 cell line
1. Thaw MDA-MB-231 cryovial (with 1mL of cells suspended
in FBS with 10% DMSO) by placing rapidly in a water
bath at 37◦C.
Note: remove the cryovial from the water bath immediately
when only a small fragment of ice is observed.
2. With a Pasteur pipette add the cell suspension to a falcon with
4mL of supplemented DMEM, drop by drop.
Note: the supplemented cell medium must be at 37◦C
before use.
3. Centrifuge at 200 g for 5min.
4. Count the cells in a hemocytometer with trypan blue to
exclude dead cells and resuspend the desired concentration in
supplemented DMEM.
5. Plate the cells in a 6-well plate (2mL of medium per well) and
incubate in a humidified environment at 37◦C, 5% CO2.
6. When cells reach an 80–90% confluency, pass the cells by
removing the medium, wash with PBS 1X and add 500 µL of
TrypLE to each well and incubate at 37◦C.
7. When cells begin to detach, add the same volume of
supplemented DMEM and centrifuge at 200 g for 5min.
8. Remove the supernatant, add supplemented DMEM and seed
in a new 6-well plate.
Isolation of peripheral blood mononuclear cells (PBMCs)
1. Dilute whole blood in PBS 1X (1:1 ratio) in a 50mL falcon and
mix well.
2. In a new 50mL falcon with Ficol, layer the blood
solution, with a Pasteur pipette, on top of Ficol in a
3:5 ratio (Ficol:blood).
Notes: perform this step very gently to avoid disturbing the
Ficol layer. The Pasteur pipette can be placed in a 45◦ angle
and the blood solution can be released directly on the wall of
the falcon.
3. Centrifuge at 1,000 g for 30min without brake.
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FIGURE 1 | Establishment of 3D co-culture of breast cancer cell line and patient-derived immune cells. (A) Scheme of the protocol for the 3D in vitro spheroids of
MDA-MB-231 cell line in co-culture with patient-derived peripheral blood mononuclear cells (PBMCs). (B) Representation of the 3D culture in 96 well plates and the
infiltration of the PBMCs. Figure performed in Biorender.
4. With a Pasteur pipette carefully remove the PBMCs layer
(between the plasma and the Ficol) to a new 50mL falcon.
5. Add 20mL of PBS 1X and centrifuge at 300 g for 5min.
6. Remove the supernatant, add 10mL of PBS 1X and centrifuge
at 200 g for 5min.
7. Count the number of PBMCs in a hemocytometer with trypan
blue to exclude the dead cells.
8. Freeze the cells in FBS with 10% DMSO in a concentration of
∼5× 106 cells/mL per cryovial.
Note: when adding the freezing medium (FBS with DMSO)
do it very gently to avoid loss of cell viability in the presence
of DMSO.
9. Store at−80◦C until further use.
3D Co-culture Assembly
The 3D co-culture ofMDA-MB-231 with patient-derived PBMCs
follows a series of consecutive steps, which can be observed in
the scheme in Figure 1.Note: check spheroid development daily in
an optical microscope to assess if spheroid is formed or to analyze
possible contaminations.
1. Day 0:
a. Prepare in advance 1.5% agarose in dH2O and
autoclave the solution.
Note: a new agarose solution should be prepared every
time a new 3D culture protocol is initiated.
b. After the autoclave and the solidification of the agarose,
place the solution in a water bath at 90◦C for 1 h.
Note: alternatively, use the agarose directly from the
autoclave, letting the solution cool down without solidifying.
c. Add 50 µL of agarose per well with a multichannel pipette
in a 96-well plate with round bottom.
Notes: perform this step rapidly as agarose can solidify. If
the agarose starts to solidify when pipetting, place it again
in the water bath. Avoid the formation of bubbles that will
compromise spheroid formation.
d. Allow to cool down for 20min.
e. Add 1,000 MDA-MB-231 cells in 200 µL of supplemented
DMEM per well.
f. Incubate in a humidified environment at 37◦C, 5% CO2.
2. Day 1:
a. Remove 100 µL of medium per well and discard.
Note: remove the medium by placing the pipette tip with a
45◦ angle and gently aspirate from the top of the well, without
touching the spheroid(s).
b. Add 100 µL of fresh supplemented medium (see recipes)
per well.
c. Incubate in a humidified environment at 37◦C, 5% CO2.
3. Day 3:
a. Remove 100 µL of medium per well and discard (see note
in 2.a).
b. Add 100 µL of fresh supplemented medium (see recipes)
per well.
c. Incubate in a humidified environment at 37◦C, 5% CO2.
4. Day 6:
a. On this day the spheroid must be fully formed (Figure 2)
and co-culture can be assembled.
b. Thaw PBMCs by placing the cryovial rapidly in a water bath
at 37◦C (see note in 2D culture section).
c. With a Pasteur pipette add the cell suspension to a falcon
with 4mL of supplemented RPMI, drop by drop.
d. Centrifuge at 200 g for 5min.
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FIGURE 2 | Area of the 3D spheroids with MDA-MB-231 breast cancer cell line increases with time. (A) Bright-field images of MDA-MB-231 spheroids at days 3, 6, 8,
and 10. Scale bars−50µm. (B) Spheroid area of MDA-MB-231 spheroids at day 3 (n = 4), day 6 (n = 7), day 8 (n = 4), and day 10 (n = 10). Data is represented as
mean ± SD, *p < 0.05, ***p < 0.001 (paired t-test).
e. Count the cells in a hemocytometer with trypan blue to
exclude dead cells and resuspend the cells with the desired
concentration in supplemented RPMI.
f. Remove 100µL of medium per well in the 96-well plate and
discard (see note in 2.a).
g. Add 100 µL per well of supplemented RPMI containing
1000 PBMCs to perform a 1:1 ratio co-culture.
h. Incubate in a humidified environment at 37◦C, 5% CO2.
Note: if using PBMCs stimulated with PMA and
ionomycin, add the same percentage of DMSO (used to
prepare ionomycin) to the wells without PBMCs or with
non-stimulated PBMCs.
5. Day 7:
a. At this stage, PBMCs are already infiltrated in the 3D
spheroid structure (Figure 3).
6. Day 8:
a. Remove 100 µL of medium per well and discard (see note
in 2.a).
b. Add 100 µL of fresh supplemented RPMI (see recipes) per
well (at this stage, chemical and/or biological compounds
can be added—see drug screening section).
Note: if the compounds are diluted in dimethyl sulfoxide
(DMSO), keep the same DMSO concentration in all the wells.
c. Incubate in a humidified environment at 37◦C, 5% CO2.
7. Day 10:
a. At this time point, the area, viability and other parameters
of the spheroids and the molecules present in their
supernatant can be analyzed.
Techniques to Characterize the Spheroids
This system allows the determination of several parameters
of the whole spheroids. First, we used Imaging techniques,
to determine the spheroid area and, by employing two cell
tracers (one red and one green), identify both cell types (tumor
and patient-derived PBMCs) and address the infiltration of
the PBMCs in the 3D tumor-like structure. Although not
employed here, immunofluorescence can also be performed
if desired, to detect distinct cellular markers, such as those
involved in tumor cell apoptosis, proliferation, or PBMCs’
activation, using confocal microscopy. Here, we have opted
for Flow Cytometry and ELISA to address the effect of
the PBMCs, with or without previous stimulation, in the
breast cancer cell line viability. Flow Cytometry was used
to determine the viability of both cell types; however, this
technique is also useful to pinpoint surface and/or intracellular
markers to distinguish cell populations and to assess levels
of immuno-activation or -suppression, for instance. ELISA
assays of the co-culture supernatant were performed to quantify
secreted IFN-γ, which is one of the main cytotoxicity-related
molecules released by effector T cells. This technique can
also be performed to analyze the level of other soluble
molecules, including cytokines, depending on the objective of
the experiment. Here we focused particularly on these methods;
nevertheless, we envisage several others that could be employed
to analyze these 3D co-cultures, such as western blot, to
assess different markers in the whole spheroid (independently
of the cell population), real-time qPCR, to address gene
expression, and fluorescence activated cell sorting (FACS) to
separate different cell populations in order to further study
them individually.
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FIGURE 3 | Patient-derived immune cells are able to infiltrate the 3D spheroid of MDA-MB-231 breast cancer cell line. (A) Bright field of MDA-MB-231 spheroid (left
panel), patient-derived PBMCs stained in red with a cell tracer dye (middle panel) and the two photos merged (right panel), at day 7 of the culture (24 h after the
addition of the PBMCs); 10x objective, scale bar 50µm. (B) Confocal images of 3D spheroids of MDA-MB-231 cell line (stained in green with CFSE) and
patient-derived PBMCs (stained in red with a cell tracer dye). Stills were acquired with a 10x objective for different Z focal planes, to demonstrate the immune
infiltration in a 3D structure. Images were assembled with Image J; scale bar 50µm. (C) Spheroid area of MDA-MB-231 cells in monoculture (n = 10) and in
co-culture with breast cancer patient-derived PBMCs (+PBMCs, n = 14) at day 10 of the culture. Data are represented as mean ± SD.
Flow Cytometry
Different cell surface or intracellular markers can be assessed by
Flow Cytometry after dissociation of the spheroid and incubation
with target fluorescent monoclonal antibodies. Additionally,
the viability of the spheroid cells could be determined using
fluorescent viability dyes. Here we used a viability dye to assess
the effect of the addition of unstimulated/stimulated breast
cancer patient-derived PBMCs in the tumor cells. Additionally, to
distinguish tumor and immune cells, the pan-leukocyte marker
CD45 was used.
1. Collect the spheroids at day 10 by pipetting the total 200 µL
from each well.
Note: perform this step with a P1000 micropipette.
2. Transfer the spheroid to a 1.5mL microtube and disrupt the
structure by pipetting up and down several times.
Note: use at least 6 spheroids per condition.
3. Centrifuge at 115 g for 5min.
4. Remove the supernatant and resuspend the pellet in PBS 1X.
5. Add 1µL of BDHorizonTM Fixable Viability Stain 450 permL
of PBS 1X.
Note: leave at least 100 µL of cell suspension for the
unstained condition.
6. Incubate in the dark, at 4◦C for 20min.
7. Centrifuge at 300 g for 5min.
8. Remove the supernatant and resuspend in PBS 1X
9. Add 2 µL of anti-CD45-PercP per 100 µL of PBS 1X.
Note: leave at least 100µL of cell suspension in viability stain
for fluorescence minus one control.
10. Incubate 15min at room temperature in the dark.
11. Centrifuge at 300 g for 5min.
12. Remove the supernatant and add PBS 1X or FlowFix.
13. Analyze in the flow cytometer.
14. Perform data analysis in FlowJo (see Figure 4A).
ELISA
Cytokines or other molecules released to the extracellular milieu
can be quantified by ELISA (see Figure 4D).
Frontiers in Oncology | www.frontiersin.org 6 August 2020 | Volume 10 | Article 1543
Saraiva et al. 3D Cancer and Immune Co-culture
FIGURE 4 | Previous stimulation increases the cytotoxicity of patient-derived immune cells against tumor cells. (A) Representative histogram of the flow cytometry
analysis of the viability of MDA-MB-231 in monoculture (black line), in co-culture with non-stimulated PBMCs (blue line) and in co-culture with previously stimulated
PBMCs (red line); the percentage of live cells in each condition is represented. (B) Percentage of viable breast cancer cells (MDA-MB-231) in monoculture (black bar, n
= 10), in co-culture with PBMCs (+PBMCs (No St), blue bar, n = 16) and in co-culture with PMA/ionomycin stimulated PBMCs (+PBMCs (St), red bar, n = 16). (C)
Data on the viable tumor cells in co-culture (same as in B) represented as connected dots, to highlight the effect of PBMCs stimulation in individual cases. (D)
Correlation (Spearman r) between the viability of the MDA-MB-231 cell line and the production of IFN-γ, detected in the co-culture supernatant and quantified by
ELISA. Data is represented as mean ± SD. Mann-Whitney test was applied in (B) and a paired t-test was used in (C), *p < 0.05, ****p < 0.0001. All the wells have the
same quantity of DMSO, as this reagent was used to prepare ionomycin.
1. Collect the spheroids at day 10 by pipetting the total 200 µL
from each well (see note in flow cytometry section).
2. Transfer the spheroid to a 1.5mL microtube.
Note: use at least 6 spheroids per condition.
3. Centrifuge at 115 g for 5min.
4. Remove the supernatant to a new 1.5mL microtube.
5. Centrifuge at 375 g for 10min to remove any cellular debris.
6. Collect the supernatant to a new 1.5mL microtube.
7. Aliquot and store at−80◦C or use immediately.
8. Perform the ELISA assay following the
manufacturer’s instructions.
Imaging
Image acquisition can be performed in bright field or
fluorescence. Here, we have used bright field snapshots to
determine the spheroid area in Image J software. However,
other spheroid parameters could also be determined, such
as the diameter and volume based on the same images. To
diminish the operator bias, an automatic threshold was applied
to the image (Image—Adjust—Threshold) and quantification
of the area was performed in the appropriate tear-down
menu (Analyze—Measure).
For fluorescence, one of the two distinct staining methods—
cell tracers or immunostaining, could be employed and
although here we just used cell tracers, we opted to
described both:
1. Cell tracers (see Figure 3).
a. Following the manufacturer’s instructions, resuspend
MDA-MB-231 cells in PBS 1X before the start of the
3D culture.
b. Stain with 5mM of Cell Trace CFSE proliferation kit for
20min in the water bath at 37◦C.
c. Add supplemented DMEM and incubate in the water bath
at 37◦C for 5min.
d. Centrifuge at 115 g for 5min.
e. Resuspend in supplemented DMEM in the
desired concentration.
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f. Perform the 3D culture as above.
g. Place the PBMCs in unsupplemented RPMI and add 5mM
of CellTrackerTM Orange CMTMR.
h. Incubate in the water bath at 37◦C for 30min.
i. Centrifuge at 115 g for 5min.
j. Remove the supernatant and add fresh
supplemented RPMI.
k. Perform the co-culture as explained above.
Acquire images of the spheroids in the co-culture directly in the
plate wells, after 24 h, in a fluorescence or confocal microscope
with lasers 488 and 568.
Here, stills were acquired with a 10x objective for different Z
focal planes, to demonstrate the immune infiltration (red cells)
in the 3D tumor-like structure (green). Images were assembled
in Image J.
2. Fixing followed by immunostaining (not employed here)
a. At the end of the co-culture, remove the medium.
Note: be very careful to avoid disturbing the spheroid.
b. Add 200 µL of 4% paraformaldehyde (PFA) and incubate
for 20 min.
Note: alternatively, remove 100 µL of medium and add
100 µL of PFA. Wait 5min to stabilize the spheroid, remove
another 100µL of mediumwith PFA and add 100µL of fresh
PFA and incubate for 20min.
c. Remove the PFA and perform the staining.
Note: it is recommended to perform the staining on the
same plate and observe in the microscope with the same plate
to minimize spheroid destabilization.
Statistical Analysis
Statistical analysis was performed in GraphPad Prism v7 and
statistical significance was considered for p < 0.05. Comparison
between samples was performed by a nonparametric Mann-
Whitney test or paired t-test and correlations were calculated
with Spearman r-test.
Potential Applications
With this 3D model, employing individual patient-derived
immune cells, several applications can be achieved, such as the
study of the cross-talk between immune cells and breast cancer
cells or a medium-throughput drug screening, in a precision
medicine approach. Indeed, here we propose the use of this
platform, precisely as a tool to test different immune-modulators
to improve breast cancer treatments.
Drug Screening
To perform a drug screening, any soluble drug (e.g.,
chemotherapy compounds), immune checkpoint inhibitor
(such as the PD-1/PD-L1 axis), agonist antibody or small
molecule, etc. can be added to the 3D co-culture in order to
either kill the cancer cells directly or to promote killing mediated
by the immune cells. The optimal day to add the compound is
on day 8 (see Figure 1), so that PBMCs are already infiltrated
in the tumor-like structure. The effect of the molecule can be
observed after 2 days (day 10 of culture). Alternatively, immune-
modulators that can alter the behavior of the immune cells, can
be added only to the PBMCs, before their addition to the 3D
culture (day 6). In this case, other drugs (e.g., chemotherapeutic
compounds) can be added in the same experiment on day 8, and
the collective effect observed on day 10.
As a proof-of-concept, here we disclose the use of a canonical
immune-modulator—PMA/ionomycin—that acts as a stimulator
of the PBMCs, leading to their activation and potentiating
their effector functions. This stimulus was added directly to the
PBMCs at day 6. The effect of stimulated PBMCs on the viability
of tumor cells was observed at day 10 by flow cytometry (see the
section techniques to characterize the spheroids).
Note: perform a dose-response curve to assess the optimal drug
concentration for the screening.
1. At day 6 of 3D co-culture:
a. Remove 100 µL of medium per well and discard.
Note: remove themedium by placing the pipette tip with a 45◦
angle and aspirate from the top of the well, without touching
the spheroid.
b. Add 1000 PBMCs suspended in 100 µL of supplemented
RPMI per well, previously stimulated with 35 ng/mL PMA
and 1µg/mL of ionomycin.
c. Incubate in a humidified environment at 37◦C, 5% CO2.
2. At day 10:
a. Collect the spheroids by pipetting the total 200 µL from
each well.
Note: perform this step with a P1000 micropipette.
b. Transfer the spheroid to a 1.5mL microtube and disrupt
the structure by pipetting up and down several times.
Note: use at least 6 spheroids per condition.
c. Centrifuge at 200 g for 5min.
d. Remove the supernatant and resuspend the pellet in
PBS 1X.
e. Perform the staining for Flow Cytometry.
Anticipated Results
In this protocol, we reveal a reproducible, simple, quick, and
economical method to construct 3D tumor-like structures with
infiltrated immune cells derived from breast cancer patients
(Figure 1). This method was developed for the cell line MDA-
MB-231, normally described as challenging to form spontaneous
3D structures (19, 20).
This cell line is a representation of the most difficult to treat
breast cancer subtype, which is triple negative breast cancer
(TNBC).We have performed a characterization of several surface
markers of MDA-MB-231 cells (Figure S1), following the Flow
Cytometry methods in Techniques section. Interestingly, we
observed that this cell line has a cancer stem cell-like phenotype
(CD44high/CD24low), which can be correlated with less effective
treatment response in breast cancer (24). This cell line is also
positive for the immunosuppressive trait PD-L1, and CD47
(Figure S1), which can be seen as possible targets to develop
directed therapies. PD-L1 is an immune checkpoint, which can
inhibit the effector function of T cells; while CD47might help the
tumor cells to evade phagocytosis by phagocytic immune cells
(25). The platform here developed, bearing embedded immune
Frontiers in Oncology | www.frontiersin.org 8 August 2020 | Volume 10 | Article 1543
Saraiva et al. 3D Cancer and Immune Co-culture
cells, could allow to test these and other several immune-
modulator agents to develop new TNBC-specific therapies.
To validate our protocol, we have also performed a co-
culture protocol with MCF-7 cell line, which is from the most
frequent subtype of breast cancer (estrogen receptor), using a
similar procedure. Although both cell lines share some features
(Figure S1), such as the expression of CD47, MCF-7 lacks the
expression of PD-L1 at its surface. The spheroids with this cell
line were fully formed at day 3 (Figure S2).
MDA-MB-231 were seeded in round bottom plate in low-
attachment conditions. A uniform spheroid of MDA-MB-231
is completely formed and compact at day 6 (Figure 2A); in
addition, the spheroid formation was highly reproducible and
none had their morphology compromised. Bright-field images
were collected every 2 days (day 6, 8, and 10) and the spheroid
area was analyzed with Image J. Briefly, an automatic threshold
can be applied to the image, to reduce the operator bias (Image—
Adjust—Threshold) and quantification of the area can be
performed (Analyze—Measure). Interestingly, we observed that
it increases from day to day (Figure 2B), showing the capacity
of the cancer cells to divide and proliferate, which mirrors
their wellbeing in the referred conditions and their capacity to
maintain the 3D structure. Likewise, MCF-7 spheroids showed
a similar growing pattern (Figure S2). Besides assessing spheroid
area, other analysis can be performed by Image J, such as spheroid
diameter, fluorescence quantification, circularity, to name a few.
After the 3D formation, we added breast cancer patient-
derived PBMCs, in a 1:1 ratio, replicating more accurately than
other reported systems, the in vivo likely proportion of immune
cells to the tumor, as we have previously demonstrated (3). The
characteristics of the patients enrolled in this study are described
in Table S1. We observed that after 24 h only, the PBMCs were
able to infiltrate the tumor-like structure (Figures 3A,B), without
affecting the spheroid area (Figure 3C). This result was achieved
by imaging techniques using a cell tracer to distinguish the
immune cells (CellTrackerTM Orange CMTMR) and another to
distinguish tumor cells [carboxyfluorescein succinimidyl ester
(CFSE)]). Additionally, if desired, the employment of the CFSE
dye has the advantage of following the tumor cells’ proliferation
(the dye will become more diluted with every cellular division).
Likewise, immunofluorescence for any kind of cell marker can
be performed after spheroid fixation (see Imaging protocol in the
Techniques section). Identical PBMCs’ infiltration in the whole
3D conformation of the tumor-like structure was observed for
MCF-7 spheroids (Figure S3).
Several techniques, besides imaging, could be applied to
this 3D co-culture, such as immunophenotyping by flow
cytometry, western blot, real-time qPCR, or ELISA of the culture
supernatant, to name a few, to investigate in-depth how the
immune cells of a particular patient react to cancer cells. For
instance, it may help to understand which subpopulation of
lymphocytes, among the effectors or regulatory ones, become
more activated and able to proliferate; which cytokines are
being produced or which receptors and co-receptors are
being stimulated.
Besides showing great potential as a platform to study the
complex interaction between cancer and the immune system of
particular individuals, this system is particularly suited to access
different strategies to immune-modulate in different patients the
anticancer immune response.
Indeed, here we assessed the viability of the tumor cells,
by flow cytometry, in the presence of patient-derived PBMCs
with or without previous stimulation (Figure 4). Interestingly,
we observed that the addition of PBMCs from the majority
of breast cancer patients to the cancer cells spheroid reduces
the viability of the tumor cells (p = 0.02, Figures 4A,B),
showing the cytotoxic profile against cancer cells of patient-
isolated PBMCs. However, PBMCs from certain patients barely
affect the viability of cancer cells, suggesting that the range
of the immune responses varies widely. This may be due to
impaired activity of effector immune cells in patients where an
immunosuppressive environment predominates. Therefore, we
also used PBMCs previously stimulated ex vivowith the canonical
stimulus of PMA/ionomycin and, after 4 days in co-culture,
we observed that stimulated PBMCs reduced even further the
viability of the MDA-MB-231 cells (p < 0.0001, Figures 4A,B),
indicating that activated immune cells have a higher cytotoxic
capacity. Furthermore, when comparing non-stimulated with the
stimulated condition, there is a significant difference in their
effect on tumor cells (p < 0.0001, Figure 4B). Notably, PBMCs
from 16 breast cancer patients when PMA/ionomycin stimulated,
similarly became more efficient in exerting their cytotoxicity
towards cancer cells (Figure 4C). Interestingly, the same effect
was observed for the co-culture with patient-derived PBMCs and
MCF-7 tumor cell line (Figure S4), suggesting that immuno-
modulating the PBMCs (at least with the canonical stimulus here
employed) could improve their cytotoxicity against breast cancer
lines with different characteristics.
The analysis of IFN-γ level in the co-culture, performed with
the stimulated PBMCs, by ELISA, revealed a negative correlation
between the viability of tumor cells in the co-culture and the
quantity of released IFN-γ into the supernatant (Figure 4D and
Figure S4D), in line with the idea that this cytokine is essential
for the activity of cytotoxic T cells (26). Thus, the level of this
molecule in the supernatant of the co-culture could also be a
readout of the extension of the immune response toward the
tumor cells.
Although PMA/ionomycin is a canonical stimulus, it is
not compatible with clinical use. Nonetheless, the results here
described suggests that we could indeed modulate the antitumor
immune response and that we could use the 3D in vitro system
here developed to identify which clinical grade stimulus is more
indicated to boost the antitumor immune response of a particular
patient. For instance, as the cell line here employed is PD-
L1+, this system could be used to test the effect of anti-PD-1
or anti-PD-L1 alone or in combination with other drugs, such
as immune-based small molecules or even chemotherapeutic
agents, to address, in a precision medicine approach, the best
treatment for each patient.
Here we demonstrate one of the applications of this
protocol—to assess the effect of potential immune-modulators
on individual PBMCs’ capacity to eliminate tumor cells.
Nevertheless, this protocol can be adapted for other scenarios,
including different breast cancer cell lines or cell lines from
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different types of cancer. Additionally, although the allogeneic
system here presented appears suitable to evaluate the antitumor
response of patients’ immune cells, we envisage that patient-
derived tumor cells can also be incorporated in this protocol to
obtain an eventually more clinical relevant autologous system.
Nevertheless, modifications to the protocol have to be made
to obtain a 3D patient-derived tumor culture—from a surgical
specimen, a cell suspension has to be obtained (either by
mechanical or enzymatic disaggregation) and cultured on 2D to
expand. Expanded patient-derived tumor cells can then be added
to agarose-coated wells and allow to form a 3D spheroid. The
time from a 2D culture and the application of the primary tumor
cells to a 3D conformation, as well as the time to obtain the 3D
structure would have also to be optimized.
DISCUSSION
In this manuscript, we reveal an optimized method to form 3D
spheroids with the breast cancer cell line MDA-MB-231 and
patient-derived immune cells, specially foreseeing its application
in the discovery of new immunotherapeutic strategies that could
improve individually breast cancer patient care. The cell line
here employed is particularly used to study the most difficult
to treat type of breast cancer—triple negative breast cancer
[TNBC, (21)]. Since TNBC has no specific molecular target,
the main therapeutic strategy used for these patients is systemic
chemotherapy, but the prognosis tends to be poorer when
compared to other types of breast cancer.
An important role of the immune system is to identify and
eliminate tumors. Tumor-associated antigens are recognized by
immune cells that mount an immune response against tumor
cells which may contribute to eliminate chemotherapy-resistant
tumor cells. However, tumors develop several mechanisms to
escape immune recognition. For instance, when T cells interact
with tumors, they may deliver several potential inhibitory
signals, including lack of proper co-stimulation and induction
of immunosuppressive T regulatory cells (4). Therefore, an
important challenge in cancer treatment is the identification
of effective strategies for enhancing its clinical efficacy. The
field of immuno-oncology has been rapidly growing and
several immunological molecules have been exploited in the
latest years to overcome the tumor’s effort to evade the
immune system, with great success in some types of cancers
(e.g., melanoma, lung cancer). The immunotherapy could
be achieved by blocking pathways that limit the immune
response, such as the PD-1/PD-L1 axis, the CTLA-4 or the T
regulatory cells; or using immune system stimulating agents,
such as pro-inflammatory cytokines or other agonists of co-
stimulatory receptors to enhance the activity of cytotoxic T
cells (4).
Due to the unmet clinical need to find a target and an
efficient therapy for TNBC, this type of cancer is the main
breast cancer subtype enrolled in immuno-oncology studies (2,
21). Interestingly, here we observed that the cell line MDA-
MB-231 (TNBC) besides exhibiting a cancer stem cell-like
(CD44high/CD24low) phenotype, is also positive for PD-L1 and
CD47 (Figure S1), two immune-related markers that can be
further explored as new alternative target therapies. Actually,
in cases of metastatic TNBC, immunotherapies against PD-
L1 are already approved, namely Atezolizumab along with
paclitaxel (27). Therapies against CD47 are also being applied
in several clinical trials, although not specifically in breast
cancer (25).
However, considering the wide range of antitumor immune
responses, even against the same type of tumor, due to individual
traits, it is important to further develop tailored treatments for
TNBC patients. Regularly, only late-stage patients are given the
opportunity to receive novel therapies, which might offer the
potential for long-term disease control (although those therapies
have shown benefits only in a small percentage of patients); while
patients with less advanced disease never reached the chance of
being treated with off label medications.
Thus, 3D cultures with patient-derived material provide a
simple-to-use and rapid system to test ex vivo several new
therapeutic strategies, that might be later translated into the
patients. Although attempts have been made to successfully form
spheroids withMDA-MB-231 cell line (19, 20), most use scaffold-
based techniques. Here, we disclose a simple technique that
allowed the formation of a uniform and compact 3D structure
with this cell line, that has the advantage of being simpler,
cheaper, and requiring only a few cells (1000) per well/condition.
Indeed, Froehlich et alwere able to form spheroids but only when
10,000 MDA-MB-231 cells were cultured per well in Matrigel
(19) and, similarly, Ivascu et al achieved compact spheroids with
this cell line when 5,000 or 10,000 cells were seeded per well.
These last authors even screened several additives to increase
3D compaction (including collagen type IV, fibronectin, laminin,
heparan sulfate proteoglycan, and chondroitin sulfate) but did
not observe spheroid formation after 14 days. The 3D formation
was only observed when reconstituted basement membrane was
added to the culture. The use of agarose provides a non-adhesive
structure with a concave surface shape and without cellular
recognition sites, forcing the cells to aggregate and form compact
3D structures.
Furthermore, we included breast cancer patient-derived
peripheral blood mononuclear cells (PBMCs) in the 3D culture
to allow a representation of each individual immune response to
the tumor and therefore obtain a platform appropriate to screen
different strategies that could potentially engage the immune cells
of a particular patient to recognize and eradicate tumor cells.
Indeed, we were able to build this co-culture in a 1:1
ratio, which is another advantage when compared to other
3D co-cultures with tumor and immune cells, where a hardly
physiological, significantly higher [for instance 1:10 (23)],
amount of immune cells is employed. Likewise, when using
patient-derived material, the use of the minimum amount of
cells is a gain. As we have previously observed, in breast cancer
patients, the immune infiltration is never higher than 50% of the
tumor mass (3), the 1:1 ratio here implemented was another step
toward in vivo replication.
The method here described for the co-culture is
straightforward. Once optimized the protocol, namely the
time needed for the spheroid formation and the number of
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FIGURE 5 | Model of the developed platform for drug screening. With the developed 3D co-culture system here described it is possible to perform a drug
screening—multiple approaches per plate. For instance, the use of antibodies against checkpoint inhibitors (anti-PD-1, -PD-L1, -CTLA-4, -Tim3), or
immune-modulators, such as PMA/ionomycin. These strategies can be used alone or in combination with standard chemotherapeutic agents with the ultimate goal of
increasing the expression of IFN-γ, Granzyme B, and Perforin, hence the cytotoxic T cells effector function, in order to eliminate tumor cells. Figure performed in
Biorender.
each cell population to use in the co-culture in order to reach
the desired ratio of 1:1, we have encountered no significant
limitations or challenges.
The functional readouts used were the viability of tumor
cells (evaluated by flow cytometry after harvesting the spheroids
and staining the cells with a viability dye and a pan-leucocyte
antibody to distinguish immune from cancer cells) and the
production of IFN-γ by ELISA. However, other evaluation
methods could be employed. For instance, live imaging to
visualize the immune infiltration or to assess tumor cell
apoptosis; real-time qPCR to quantify the expression of genes
related to cell death and to immune-activation cascades; western
blot or immunofluorescence to analyze specific markers.
As a proof-of-concept of the application of the implemented
3D system, we used the canonical stimulus PMA/ionomycin to
increase the cytotoxic profile of breast cancer patient-derived
PBMCs. Indeed, we observed that stimulated PBMCs were
able to reduce significantly the viability of MDA-MB-231 and
produce more IFN-γ when previously stimulated, corroborating
that these abilities could be modulated and that the established
protocol creates a physiologically relevant environment for a
medium-throughput screening of clinical grade immune-based
compounds. For comparison, we used the estrogen receptor
positive breast cancer cell line—MCF-7, and observed a similar
effect of the patient-derived PBMCs on the tumor cells’ viability.
In fact, in the future, an aliquot of patients’ blood could be
immunophenotyped by flow cytometry to assess the expression
of the inhibitory and/or stimulatory co-receptors present at
the main T cell subpopulations, therefore checking the more
probable targets. Then, based on this information, monoclonal
antibodies designed to block inhibitory pathways such as the PD-
1/PD-L1 axis or other immune checkpoints—CTLA4, Tim-3 (T-
cell immunoglobulin domain and mucin domain 3) and LAG-3
(lymphocyte-activation gene 3)—or to stimulate stimulatory co-
receptors—CD137, GITR (glucocorticoid-induced TNFR family
related gene), OX40 and CD27—or small molecules, either
agonist or antagonists, or cytokines could be incorporated in
the 3D co-culture assay with the PBMCs from the same patient.
Therefore, we can say that our platform is designed to develop
immunotherapies in a “personalized medicine” way, even if the
3D cellular structure that mimics the tumor employs breast
cancer cell lines, because the main target of the therapies to be
tested are the individual patient-derived PBMCs, that are added
in co-culture. Moreover, as it has been discussed in the field,
the combination of immunotherapies with other drugs, namely
chemotherapeutic agents, can also be evaluated on an individual
level (Figure 5).
We anticipate that some strategies should induce the
enhancement of the immune components that will result in the
activation of the tumor-reactive cytotoxic T cells, and ultimately
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in the rise of IFN-γ and cytotoxic-related molecules, such as
granzyme B and perforin, hence leading to more efficient tumor
cell killing (Figure 5). Certainly, the best strategies would be
different from patient to patient.
Due to the fact that the same quantity of PBMCs added
to the tumor-like spheroid may include different percentages
of cytotoxic T cells (depending on the patient), comparisons
of the immune-mediated killing and the effect of compounds
between different patients would be hard to establish, but we
have to keep in mind that the system here developed aims
essentially to screen potential immune-modulatory agents to
increase the immune-mediate killing individually, and not to
make comparisons between different individuals.
Moreover, the system proposed is an allogeneic system,
meaning that the T cell receptor (TCR) of the patient-
derived T cells do not match the major histocompatibility
complex (MHC) molecules present at the tumor cell line. T
cell’s alloreactivity is now a well-established phenomenon and
although its molecular basis remains enigmatic, it is becoming
more clear that many T cells recognize alloantigens with
high specificity (28). Thus, interactions of tumor spheroids
with T cells and the impact of immune-modulators on tumor
spheroids fate are being explored through allogeneic co-
cultures (23), as the establishment of autologous platforms
would represent additional challenges. Indeed, our system also
demonstrated that the immune cells harvested from patients can
recognize and destroy tumor cells independently of TCR/MHC
matching, and that this ability could be improved by proper
stimulation. The alloreactivity, at least of some T cells may
explain why this is a suitable system to allow a screening
of immune based compounds with potential to improve T
cells cytotoxicity.
Although optimizations must be performed for each
patient/agent (or combination of agents) tested, namely in terms
of the concentration range, which can be time-consuming, this
protocol is economic and easy to handle, allowing the screening
of several strategies in one single plate and it can be implemented
in any laboratory with cell culture facilities. Though here we used
patient-derived PBMCs regardless of the breast cancer subtype
of the donors, in the future this established model with MDA-
MB-231 cell line should be used to test immune-modulators for
PBMCs derived from a patient with TNBC. In addition, this
protocol is perfectly suited to be used with PBMCs from other
sources and can be adjusted for different culture times and drug
concentration to adapt to each assay need.
Expectedly, the use of this 3D co-culture in pre-clinical tests
will contribute to the implementation of novel and more tailored
therapies that could ameliorate individual breast cancer care.
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